Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.
- Investor Dan Calugar Discusses Whether the Emergence of Quantum Computing in Algorithmic Trading Is a Game-Changer for Financial Markets
- Meet Grant Conner: The Eco-Friendly Gold Supplier Revolutionizing the Jewelry Industry
- MBD Financials: The Revolutionary Platform Redefining How We Harness the Digital Age to Empower Others
Drugs and chemicals maker Merck KGaA (MRCG.DE) said it agreed to acquire Sigma-Aldrich (SIAL.O) for $17 billion in cash to boost its Merck Millipore lab supplies business in the biggest takeover in the German group's history, lifting its shares.
German pharmaceutical company Merck KGaA will acquire AZ Electronic Materials for GBP1.6 billion. Merck will pay AZ's existing stockholders GBP403.5 in cash for each share.
Bids, mergers, acquisitions and disposals involving European, U.S. and Asian companies.